Literature DB >> 1334118

Inhibition of mouse mammary tumor virus-induced T cell responses in vivo by antibodies to an open reading frame protein.

H Acha-Orbea1, L Scarpellino, A N Shakhov, W Held, H R MacDonald.   

Abstract

Minor lymphocyte stimulating (Mls) antigens specifically stimulate T cell responses that are restricted to particular T cell receptor (TCR) beta chain variable domains. The Mls phenotype is genetically controlled by an open reading frame (orf) located in the 3' long terminal repeat of mouse mammary tumor virus (MMTV); however, the mechanism of action of the orf gene product is unknown. Whereas predicted orf amino acid sequences show strong overall homology, the 20-30 COOH-terminal residues are strikingly polymorphic. This polymorphic region correlates with TCR V beta specificity. We have generated monoclonal antibodies to a synthetic peptide encompassing the 19 COOH-terminal amino acid residues of Mtv-7 orf, which encodes the Mls-1a determinant. We show here that these antibodies block Mls responses in vitro and can interfere specifically with thymic clonal deletion of Mls-1a reactive V beta 6+ T cells in neonatal mice. Furthermore, the antibodies can inhibit V beta 6+ T cell responses in vivo to an infectious MMTV that shares orf sequence homology and TCR specificity with Mtv-7. These results confirm the predicted extracellular localization of the orf COOH terminus and imply that the orf proteins of both endogenous and exogenous MMTV interact directly with TCR V beta.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1334118      PMCID: PMC2119446          DOI: 10.1084/jem.176.6.1769

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  21 in total

Review 1.  T-cell reactivity and tolerance to Mlsa-encoded antigens.

Authors:  H R MacDonald; A L Glasebrook; R Schneider; R K Lees; H Pircher; T Pedrazzini; O Kanagawa; J F Nicolas; R C Howe; R M Zinkernagel
Journal:  Immunol Rev       Date:  1989-02       Impact factor: 12.988

2.  Two monoclonal rat antibodies with specificity for the beta-chain variable region V beta 6 of the murine T-cell receptor.

Authors:  J Payne; B T Huber; N A Cannon; R Schneider; M W Schilham; H Acha-Orbea; H R MacDonald; H Hengartner
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

Review 3.  T-cell recognition of minor lymphocyte stimulating (Mls) gene products.

Authors:  R Abe; R J Hodes
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

4.  Inhibition of antigen-induced T-cell clone proliferation by antigen-specific antibodies.

Authors:  G Corradin; H D Engers
Journal:  Nature       Date:  1984 Apr 5-11       Impact factor: 49.962

5.  Characterization of a murine monoclonal antibody specific for an allotypic determinant on T cell antigen receptor.

Authors:  U D Staerz; H G Rammensee; J D Benedetto; M J Bevan
Journal:  J Immunol       Date:  1985-06       Impact factor: 5.422

6.  Clonal deletion of V beta 14-bearing T cells in mice transgenic for mammary tumour virus.

Authors:  H Acha-Orbea; A N Shakhov; L Scarpellino; E Kolb; V Müller; A Vessaz-Shaw; R Fuchs; K Blöchlinger; P Rollini; J Billotte
Journal:  Nature       Date:  1991-03-21       Impact factor: 49.962

Review 7.  Mls--a retrovirus exploits the immune system.

Authors:  H Acha-Orbea; E Palmer
Journal:  Immunol Today       Date:  1991-10

8.  Detection and characterization of a glycoprotein encoded by the mouse mammary tumor virus long terminal repeat gene.

Authors:  C Brandt-Carlson; J S Butel
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

9.  Postnatal disappearance of self-reactive (V beta 6+) cells from the thymus of Mlsa mice. Implications for T cell development and autoimmunity.

Authors:  R Schneider; R K Lees; T Pedrazzini; R M Zinkernagel; H Hengartner; H R MacDonald
Journal:  J Exp Med       Date:  1989-06-01       Impact factor: 14.307

10.  Structural analysis of a mouse mammary tumor virus superantigen.

Authors:  Y Choi; P Marrack; J W Kappler
Journal:  J Exp Med       Date:  1992-03-01       Impact factor: 14.307

View more
  9 in total

1.  New superantigen specificity created by two amino acid replacements.

Authors:  O A Rosenwasser; S Fairchild; K Tomonari
Journal:  Immunogenetics       Date:  1993       Impact factor: 2.846

2.  Tcrb-V12-specific superantigens encoded by mouse mammary tumor proviruses.

Authors:  K Tomonari
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

3.  Identification of key amino acids of the mouse mammary tumor virus superantigen involved in the specific interaction with T-cell receptor V(beta) domains.

Authors:  F Baribaud; S Wirth; I Maillard; S Valsesia; H Acha-Orbea; H Diggelmann
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

Review 4.  Bacterial and viral superantigens: roles in autoimmunity?

Authors:  H Acha-Orbea
Journal:  Ann Rheum Dis       Date:  1993-03       Impact factor: 19.103

5.  Passive immunization with neutralizing antibodies interrupts the mouse mammary tumor virus life cycle.

Authors:  M Mpandi; L A Otten; C Lavanchy; H Acha-Orbea; D Finke
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

6.  Systemic antibodies can inhibit mouse mammary tumor virus-driven superantigen response in mucosa-associated lymphoid tissues.

Authors:  D Velin; G Fotopoulos; J P Kraehenbuhl; H Acha-Orbea
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

7.  Paracrine transfer of mouse mammary tumor virus superantigen.

Authors:  M Delcourt; J Thibodeau; F Denis; R P Sekaly
Journal:  J Exp Med       Date:  1997-02-03       Impact factor: 14.307

8.  The mouse mammary tumor virus envelope gene product is required for superantigen presentation to T cells.

Authors:  T V Golovkina; A Chervonsky; J A Prescott; C A Janeway; S R Ross
Journal:  J Exp Med       Date:  1994-02-01       Impact factor: 14.307

Review 9.  Endogenous mouse mammary tumor viruses (mtv): new roles for an old virus in cancer, infection, and immunity.

Authors:  Michael P Holt; Ethan M Shevach; George A Punkosdy
Journal:  Front Oncol       Date:  2013-11-26       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.